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interval to surgery is a promising treatment because the 
pathological complete response (pCR) rate of over 20% was 
recorded. The body of evidence from studies that used 
conventionally fractionated radiochemotherapy showed that, 
with a longer interval to surgery, the pCR rate and 
downstaging increased, whereas the R0 resection rate, the 
sphincter preservation rate and the long-term oncological 
outcomes remained much the same. 
The desired effect of radiation, namely irreparable DNA 
damage which ceased clonogens division, occurs at the time 
of irradiation. A lengthening of the interval between 
radio(chemo)therapy and surgery does not produce additional 
DNA damage. With delayed surgery, there is a risk of tumour 
regrowth and the development of a cancer phenotype that 
produces distant metastases. Indeed evaluation of a labelling 
index showed the accelerated proliferation of cancer cells in 
some tumours one month after 5 x 5 Gy. PET/CT 
examinations demonstrated increased metabolic activity in 
some tumours between 6 and 12 weeks after chemoradiation. 
Thus, the long interval potentially jeopardizes oncological 
outcomes in up-front resectable cancers. This effect, 
however, was not shown in the randomized studies or in the 
meta-analysis.  
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Purpose/Objective: In patients with rectal cancer 
(chemo)radiotherapy is usually followed by low anterior 
resection (LAR) or abdominoperineal resection (APR) with 
permanent colostomy. Type of surgery depends on tumor 
localization, patient's condition and surgeons' preference. 
Until now, there is still debate which procedure is superior in 
terms of quality of life (QoL). In this study we compare QoL 
during the first six months of treatment in patients 
undergoing LAR and APR. 
Materials and Methods: This study was performed in the 
context of the ProspectIve data CollectioN Iniative on 
Colorectal cancer (PICNIC) cohort. Within PICNIC patients fill 
out standardized QoL questionnaires at start of radiotherapy 
and every 3 months thereafter. In the present study, 
participants with rectal cancer who underwent curative 
surgery following radiotherapy between February 2013 and 
September 2014 were included. QoL was measured by means 
of EORTC QLQ-C30 and CR29, at baseline, 3 and 6 months. 
Responses were transformed to a longitudinal scale and 
reported as mean or median, depending on distribution. Mean 
differences in QoL scores were calculated and categorized as 
improved, stable and worsened. Differences in QoL were 
tested on significance with the Mann-Whitney U test and Chi-
square test. 
Results: One-hundred-fourteen patients were identified, 55 
(48%) underwent APR and 59 (52%) LAR. Baseline 
characteristics between were similar for both groups, except 
for tumor location (90.9% vs. 28.8% located in lower third of 
the rectum for APR and LAR resp.) and T-stage (66.7% vs. 
83.1% T3 tumors for APR and LAR resp.). At baseline, LAR 
patients reported a higher mean score for physical function 
(90 vs. 82, p= 0.008), role function (84 vs. 72, p= 0.008) and 
global health (75 vs. 66, p= 0.013) compared to APR patients. 
After 3 months, both groups reported similar differences in 
QoL function scales. At 6 months, global health recovered in 
APR patients to baseline levels or above (only 22.6% reported 
to worsen compared to baseline), while LAR patients showed 
slower recovery (with 43.5% worsened status). At 6 months, 
APR patients had worsened body image compared to LAR 
patients (mean difference -19 (-26.7 to -11.3) vs. -11 (15.8 to 
-6.8), p=0.01), but improved stool frequency (mean 
difference +18 (7.9 to 28.8) resp. -6 (-15.4 to 3.9) p=0.003). 
Regarding symptoms, LAR patients worsened on 
embarrassment for defecation pattern, while APR patients 
worsened on urine incontinence and impotence. 
Conclusions: The impact of surgery type on QoL during the 
first six months in rectal cancer patients pretreated with 
(chemo)radiation is similar for most domains. However, 
patients who underwent APR seem to recover more quickly in 
respective of their global QoL before treatment. Symptom 
patterns were quite different between patients undergoing 
LAR or APR. These results can be helpful in counseling 
patients in treatment choice, giving the large differences in 
patients' perspective, lifestyle, and expectations of 
treatment. 
   
OC-0611   
Interim analysis of postoperative chemoradiotherapy for 
locally advanced rectal cancer: a phase 3 trial 
Y. Feng1, J. Jin1, Y. Zhu2, L. Liu2, Y. Li1 
1Cancer Hospital/InstituteChinese Academy of Medical 
Sciences, Department of Radiation Oncology, Beijing, China  
2Zhejiang Cancer Hospital, Department of Radiation  
Oncology, Hangzhou, China  
 
Purpose/Objective: To present an interim analysis of the 
trial of concurrent capecitabine and radiotherapy with or 
without oxaliplatin as adjuvant treatment for locally 
advanced rectal cancer.  
Materials and Methods: This was a multicentre, open-label, 
randomized, phase 3 study in patients with pathological stage 
II-III rectal cancer. Patients were randomized to either 
radiotherapy 45-50.4 Gy/25-28 fractions with concurrent 
capecitabine 1600 mg/m2 on days 1-14, 22-35 (Cap-RT group) 
or 45-50.4 Gy/25-28 fractions with capecitabine 1300 mg/m2 
on days 1-14, 22-35 and oxaliplatin 60 mg/m2 on weeks 1, 2, 
4, 5 (Capox-RT group). Randomization was done with 
computer-generated block-randomization codes stratified by 
centre and pathological stage (II vs. III) without masking. The 
primary endpoint was 3-year disease-free survival rate (DFS); 
secondary endpoints included overall survival rate (OS), 
locoregional failure free survival rate (LRFFS), distant 
metastasis free survival rate (DMFS), compliance, and safety. 
Safety and compliance analyses included patients as treated, 
efficacy endpoints were analysed according to the intention-
to-treat principle. This study is registered with 
ClinicalTrials.gov, number NCT00714077. 
Results: Providing 80% power to detect an increase of 3y-DFS 
from 65% to 75% (α=0.05, 2-tailed test), 570 patients were 
required. Between January 2008 and July 2014, 492 patients 
were recruited from 4 centers in China. Of these patients, 
478 were evaluable (254 in the Cap-RT group and 224 in the 
Capox-RT group), with a median follow-up of 34.6 months for 
patients alive. The 3-year DFS rate was 71.6% in the Capox-
RT group, as compared with 73.9% in the Cap-RT group (p= 
0.647). No statistically significant difference was observed in 
OS, LRFFS, and DMFS between the two groups (3-year OS: 
88.1% vs. 85.4%, p = 0.770; LRFFS: 91.9% vs. 96.1%, p = 0.079; 
DMFS: 76.1% vs. 74.3%, p = 0.934), but higher cumulative 
locoregional recurrence rate in the Cap-RT group (6.7% vs. 
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2.7%, p= 0.041). In the Capox-RT group, 85.7% (191/223) 
patients received radiotherapy on schedule and 74.9% 
(166/223) with concurrent chemotherapy on schedule, as did 
94.1% (238/253) and 92.1% (233/353) in the Cap-RT group, 
respectively. Grade 3-4 acute toxicity was observed in 38.1% 
of patients in the Capox-RT group and in 29.2% in the Cap-RT 
group (p = 0.041). Grade 3–4 tenesmus was more common in 
the Capox-RT group than in the Cap-RT group (5.4% vs. 2.0%), 
as were grade 3–4 nausea (2.2% vs. 0%), grade 3–4 vomiting 
(1.8% vs. 0%), and grade 3–4 fatigue (3.1% vs. 0.4%). 
Conclusions: The interim analysis revealed that inclusion of 
oxaliplatin into capecitabine based postoperative 
chemoradiotherapy was feasible and could decrease 
cumulative locoregional recurrence rate for patients with 
locally advanced rectal cancer.  
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Traditionally, oncology patients are inclined to follow the 
treatment advice of their physician without asking too many 
questions. However, for many patients different treatment 
options are available. Each option will have its own pros and 
cons, which may be weighed differently by individual 
patients. This calls for shared decision making (SDM) and 
patient involvement in the treatment choice. In order to 
involve patients as partners in decision making, however, 
different steps are required. Patients should be invited to 
participate in the tradeoff between options. They need 
evidence-based information on the risks and benefits of 
different options presented in a structured way, preferably 
using visual aids. And they need to be stimulated to think 
about which aspects are most important to them.  
When available, decision aids are useful tools to give patients 
evidence-based information and to help them make a 
personal tradeoff. Decision aids have proven to be effective, 
e.g. in a recent Cochrane review (2011). Knowledge 
increases, less patients remain undecided on the their 
treatment preference, more patients take an active role in 
decision making, and they are more aware of which 
treatment outcomes are most important to them. As a 
consequence, the treatment choice better fits their personal 
situation and their individual preference.  
Within radiotherapy, we studied patient involvement in the 
choice between a lower or higher radiation dose reflecting 
the tradeoff between the likelihood of cure and the 
likelihood of serious side effects. Other radiotherapy-related 
choices include radiotherapy vs. surgery, radiotherapy vs. 
best supportive care, chemoradiotherapy vs. radiotherapy 
alone or conventional fractionation vs. hyper- or 
hypofractionation.  
Some physicians may hesitate to involve cancer patients in 
treatment decisions. One reason may be that some doctors 
believe they can predict their patients preferences, so they 
don’t need to bother their patients with trade-offs. However, 
preferences for treatment and for involvement appear to be 
hard to predict for physicians, and even for patients 
themselves. Once informed, they become more active 
partners in decision making than they previously predicted, 
and their preferences can differ from what their physicians 
expected. Moreover, sharing information about the pros and 
cons of different treatment options is appreciated by the vast 
majority of patients, even by those who prefer to leave the 
ultimate decision to their physician. 
Other possible barriers for SDM are the assumptions that 
patients are unable to make a consistent choice, that it may 
be a burden for patients to take responsibility for the 
decision or that it may induce regret over the choice later 
on, especially for patients with poor outcome. However, 
research shows that patient choices are consistent with their 
values and concerns. Moreover, anxiety is not increased and 
regret, if anything, appears to be reduced, particularly in 
those patients that experience poor outcome. Finally, the 
idea that shared decision making may be too time consuming 
is not confirmed by the results of recent implementation 
studies. 
Illustrated by our research, (mis)perceptions and tips about 
shared decision making will be discussed. 
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Purpose/Objective: Based on our lab results showing that the 
Farnesyl Transferase Inihibitor, Tipifarnib induced a 
vascularization normalisation, oxygenation and 
radiosensitisation in glioblastoma (GBM) model, we 
performed a phase I-II clinical trial associating Tipifarnib with 
radiotherapy in GBM patients. The aim of this study was to 
assess by dynamic susceptibility contrast MRI (DSC-MRI) the 
effect the combined treatment on tumor perfusion. 
Materials and Methods: Eighteen patients with newly 
diagnosed GBM were included in a phase I-II clinical trial 
associating RT with Tipifarnib, they underwent conventional 
anatomical MR imaging and DSC-MRI before and two months 
after treatment (M0 and M2 respectively). Anatomic volumes 
of interest (VOIs) were defined by contrast-enhanced (CE) 
regions on post-gadolinium based T1 MR images and areas of 
hyper-intense signal on T2 MR images. Perfusion changes 
between M0 and M2 were assessed by measuring the variation 
of the median relative CBV (rCBV) inside these anatomical 
VOIs. Another voxel by voxel analysis of CBV values classified 
138,646 tumor voxels (inside the CE VOI) into High_, Normal_ 
and Low_CBVTUMOR according to the distribution of CBV in the 
contralateral normal tissue: for CBV value higher than the 
95th percentile of the normal contralateral distribution, the 
voxel was classified in the High_CBVTUMOR class (red voxels) ; 
for CBV value between the 25th and the 75th percentile, the 
voxel was classified in the Normal_CBVTUMOR class (green 
voxels) and for CBV value below the 25th percentile, the voxel 
was classified in the Low_CBVTUMOR class (blue voxels). All 
